Navigation Links
Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
Date:11/19/2007

Commences Phase I Clinical Trial of Proprietary siRNA Molecule in Acute

Renal Failure

FREMONT, Calif., Nov. 19 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, announced today that it has commenced systemic dosing in humans of its proprietary product candidate, AKIi-5, a siRNA compound discovered and developed by Quark for the treatment of Acute Renal Failure (ARF), also called Acute Kidney Injury (AKI). Based on publicly available information, Quark believes that this is the first human clinical trial involving the systemic delivery of siRNA.

The Phase I clinical trial is a multi-center, double-blind, placebo controlled, dose-escalation trial assessing the safety and pharmacokinetics of AKIi-5 administered intravenously as a single dose to patients undergoing major cardiac surgery. Patients will be enrolled in the trial in a number of centers in the United States, Europe and Israel. Quark expects to complete the trial in early 2008. Depending on the results of this trial, Quark expects to initiate a dose-ranging Phase II clinical trial measuring AKIi-5 clinical activity.

Daniel Zurr, Chief Executive Officer, commented, "The initiation of human dosing in our Phase I trial in ARF signifies a very important step in Quark's clinical program and marks an important milestone in the RNAi industry. For Quark, the trial serves to further validate the strength of our pipeline and our overall expertise in the RNAi arena. With AKIi-5 now in the clinic, RTP801i-14, which we licensed to Pfizer, in a Phase I/IIa clinical trial for the treatment of wet age-related macular degeneration, AHLi-11 in IND-enabling studies and additional RNAi-based candidate drugs in pre-clinical testing, we believe Quark has one of the most robust RNAi product portfolios in the industry.

"For the RNAi industry, the trial m
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
9. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
10. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
11. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... 2015   EVO Aesthetic Center and Wellness Spa ... non-invasive aesthetics in Lakeway, Texas ... the Astanza Duality laser. The medical spa is focused ... medical and laser procedures. Their addition of the Astanza ... solution to their tattoo regret. "The large ...
(Date:7/2/2015)... N.C. , July 2, 2015 ... assets related to the ion channel biology platform from ... been obtained as part of Pfizer,s 2011 acquisition of ... rights to the "Icagen" name and trademark.  XRPro Sciences ... services for ion channel and transporter drug discovery, combining ...
(Date:7/2/2015)... de julio de 2015 BGI anunció hoy ... alto rendimiento en Hong Kong ... Pathologists (CAP). La instalación de BGI en Hong ... de próxima generación que recibe la certificación CAP en ... estándar en prácticas de laboratorio clínico. Junto con el ...
Breaking Medicine Technology:EVO Offers Advanced Laser Tattoo Removal With Astanza Duality In Lakeway, TX 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 2Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 3Icagen Re-launched through XRpro Sciences Acquisition of Pfizer Team and Technology for Ion Channel and Transporter Drug R&D 4BGI recibe la acreditación del College of American Pathologists (CAP) 2
... of the ,Top Employers, in the Biotech and Pharmaceutical... -- ABBOTT PARK, Ill., Oct. 7 ... ... lpUnit=,PRN,; --> ... { var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
... Reportlinker.com announces that a new market research report ... U.S. Venous Access Catheter Market ... U.S. markets for venous access devices including peripherally ... dialysis catheters, implantable ports, and catheter securement devices. ...
Cached Medicine Technology:Abbott Named One of the 'Top Employers' in the Biotech and Pharmaceutical Industry by Science Magazine 2Abbott Named One of the 'Top Employers' in the Biotech and Pharmaceutical Industry by Science Magazine 3Abbott Named One of the 'Top Employers' in the Biotech and Pharmaceutical Industry by Science Magazine 4Abbott Named One of the 'Top Employers' in the Biotech and Pharmaceutical Industry by Science Magazine 5Abbott Named One of the 'Top Employers' in the Biotech and Pharmaceutical Industry by Science Magazine 6Abbott Named One of the 'Top Employers' in the Biotech and Pharmaceutical Industry by Science Magazine 7Abbott Named One of the 'Top Employers' in the Biotech and Pharmaceutical Industry by Science Magazine 8Reportlinker Adds U.S. Venous Access Catheter Market 2Reportlinker Adds U.S. Venous Access Catheter Market 3Reportlinker Adds U.S. Venous Access Catheter Market 4
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ... the newest shades of the SIGVARIS PERFORMANCE SOCKS. Since the socks were first ... and athletic trainers. Their significant popularity has inspired four new, fun shades including: ...
(Date:7/2/2015)... (PRWEB) , ... July 02, 2015 , ... ActiveBunch.com recently ... passion for social fitness. Built to function as a lifestyle community, Active Bunch allows ... the opportunity to network, meet, and participate in discussions or group events. , ...
(Date:7/2/2015)... ... July 02, 2015 , ... ... company , announced today that it has reached an agreement to acquire ... CleanItSupply.com the largest distributor of Rubbermaid Commercial Products on the web today. ...
(Date:7/2/2015)... ... July 02, 2015 , ... Octo Consulting Group, (Octo), a ... government, has announced they are among nine contractors awarded the U.S. Securities and ... contract not to exceed $250 million. , To achieve the goals of ...
(Date:7/2/2015)... OR (PRWEB) , ... July 02, 2015 , ... Hand ... During the current summer flu season, according to fresh water advocate and radio host ... on the hands. Kleyne cautions that for maximum effectiveness, hand sanitizers must be applied ...
Breaking Medicine News(10 mins):Health News:SIGVARIS is Sporting Four Brand New Colors in the Popular PERFORMANCE SOCK Product Line 2Health News:ActiveBunch.com Launches as a Social Community for People with Active Lifestyles 2Health News:CleanItSupply.com Acquires eRubbermaid.com 2Health News:Octo Consulting Group Awarded IDIQ Contract for SEC Business Management Support 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 2Health News:Summer flu season hand sanitizers are most effective when correctly applied reports fresh water advocate Sharon Kleyne 3
... Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that Richard Van der Jagt, M.D. of ... the 2009 Pan Pacific Lymphoma Conference on Monday, June 22, 2009. The conference will be ... Hawaii. , , , ... 2009 Pan Pacific Lymphoma Conference, ...
... , , , President Obama Calls For Health ... 15 The American Medical Association warmly welcomed U.S. ... Like the president, the AMA is committed to health reform this ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20081209/AMALOGO ) , ...
... MBA, FACPE, Ameritox,s Senior Vice President and Chief Medical Officer, ... for the American College of Physician Executives (ACPE), a national ... , Dr. Leider became an ACPE member 20 years ... College for 13 years teaching courses on improving the quality ...
... 16, 2009 at 9:00 a.m. Eastern Time , , ... ALXA ) announced today that it has exercised ... Allegro. The purchase of Symphony Allegro, which is subject ... 2009. , , Alexza and Symphony Capital Partners, LP ...
... June 15 Citing evidence that even a very low level ... the Council of State and Territorial Epidemiologists (CSTE) is recommending a ... adults. In a vote at the CSTE annual conference in Buffalo, ... 10 ug/dl or more in adults as "elevated" -- the same ...
... 15, 2009 (BRONX, NY) In a study ... researchers from Albert Einstein College of Medicine of Yeshiva ... HIV-positive individuals are most likely to develop deadly fungal ... of meningitis affects more than 900,000 HIV-infected people globallymost ...
Cached Medicine News:Health News:President Obama Receives Warm Welcome from AMA Physicians 2Health News:Ameritox(R) CMO Elected Chairman of the American College of Physician Executives Board 2Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 2Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 3Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 4Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 5Health News:Alexza Announces Agreement to Acquire Symphony Allegro, Including All Rights to AZ-004, AZ-104 and AZ-002 6Health News:CSTE Leads Effort to Improve Blood Lead Reporting 2Health News:CSTE Leads Effort to Improve Blood Lead Reporting 3Health News:Predicting fatal fungal infections 2
The Surgiflex WAVE is a comfortable, easy to use, versatile, and interchangeable suction-irrigation device....
... Clinicians are demanding smaller, higher performing ... clinical and operational challenges. The new ... powerful architecture for superb High Definition ... and ease-of-use; and a versatile suite ...
The Cardiff Acuity Test is designed specifically for,acuity measurement in children aged 1 to 3 years. The,test is also helpful with other age groups with,intellectual impairment, dementia, hea...
... InfinixTM CF-i/SP brings revolutionary flexibility to ... enables operators to move the C-arm ... to obtain the optimal angle for ... features an 8-inch cardiac flat panel ...
Medicine Products: